Illuminating Current Pitfalls in Optimal Photobiomodulation Device Development and Assessment for Treating Hair Loss

The article highlighted significant gaps in the understanding and study of photobiomodulation (PBM) for hair growth, emphasizing the need for identifying optimal wavelengths and dosing. It pointed out the influence of regulatory and cost factors on device development, with many manufacturers opting for the less rigorous FDA 510K clearance process, which does not require proof of efficacy. The study noted that current PBM devices often use similar wavelengths, potentially due to commercial motivations rather than efficacy. The article also discussed the biphasic dose response, where both too low and too high doses can inhibit PBM stimulation. Despite promising results from randomized controlled trials, methodological flaws, such as lack of individualized dosing and issues with hair counting methods, were identified. The article concluded that while PBM shows potential for treating hair loss, further research is needed to optimize its use, and recommending these devices may be premature.